Guardant HealthNASDAQ: GH

After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved t.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. TIME solicited nominations across sectors, and polled its global network of contributors and correspondents, as well as outside experts. TIME editors then evaluated companies on key factors, including impact, innovation, ambit.

Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)'s Medical Devices Advisory Committee has strongly recommended FDA approval of the company's Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. The recommendation signals the advisory committee panel's consensus.

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health's blood test to screen for colorectal cancer in average-risk adults. The panel meetin.

Guardant Health, Inc. (Nasdaq: GH) will share findings from two real-world studies at the 2024 Digestive Disease Week (DDW) conference in Washington, DC, showcasing the effectiveness of the Shield™ test in colorectal cancer (CRC) screening. According to AmirAli, lack of CRC screening is a common issue among eligible American adults due to the discomfort and inconvenience of current screening methods.

In addition to examining Wall Street's expectations for Guardant Health's financial performance, it is important to analyze projections for other important metrics in order to better assess the company's performance in the first quarter of 2024.